Sökning: onr:"swepub:oai:DiVA.org:uu-308259" >
A retrospective cha...
A retrospective chart review of pirfenidone-treated patients in Sweden : the REPRIS study
-
- Sköld, Carl Magnus (författare)
- Karolinska Institutet
-
- Janson, Christer (författare)
- Uppsala universitet,Lungmedicin och allergologi,Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
-
- Elf, Asa Klackenberg (författare)
- InterMune Nord AB, Stockholm, Sweden.;Roche AB, Stockholm, Sweden.,InterMune Nordics AB, Stockholm, Sweden; Roche AB, Stockholm, Sweden
-
visa fler...
-
- Fiaschi, Marie (författare)
- Roche AB, Stockholm, Sweden.
-
- Wiklund, Kerstin (författare)
- PCG Clin Serv, Uppsala, Sweden.,PCG Clinical Services, Uppsala, Sweden
-
- Persson, Hans Lennart (författare)
- Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Lungmedicinska kliniken US
-
visa färre...
-
(creator_code:org_t)
- 2016-07-18
- 2016
- Engelska.
-
Ingår i: EUROPEAN CLINICAL RESPIRATORY JOURNAL. - Järfälla : Informa UK Limited. - 2001-8525. ; 3
- Relaterad länk:
-
https://www.tandfonl...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that usually results in respiratory failure and death. Pirfenidone was approved as the first licensed therapy for IPF in Europe based on phase III trials where patients with a forced vital capacity (FVC) >50% of predicted were included. The aim of this study was to characterise patients treated with pirfenidone in Swedish clinical practice and to describe the adherence to the reimbursement restriction since reimbursement was only applied for patients with FVC below 80% of predicted. Methods: This was a retrospective, observational chart review of IPF patients treated with pirfenidone from three Swedish university clinics. Patients initiated on treatment during the period 28 June 2012 to 20 November 2014 were included. Data on patient characteristics, basis of diagnosis, treatment duration, quality of life, and adverse drug reactions (ADRs) were collected from medical charts. Results: Forty-four patients were screened and 33 were included in the study. The mean treatment duration from start of pirfenidone until discontinuation or end of study was 38 weeks. At the initiation of pirfenidone treatment, FVC was 62.7% (12.1) [mean (SD)], diffusion capacity (DLco) was 45.1% (13.8) of predicted, and the ratio of forced expiratory volume on 1 sec (FEV1) to FVC was 0.78 (0.1). The percentage of patients with an FVC between 50 and 80% was 87%. Ten of the patients had ADRs including gastrointestinal and skin-related events, cough and signs of impaired hepatic function, but this led to treatment discontinuation in only two patients. Conclusion: Data from this chart review showed that adherence to the Swedish reimbursement restriction was followed in the majority of patients during the study period. At the start of pirfenidone treatment, lung function, measured as FVC, was lower in the present cohort of Swedish IPF patients compared with other registry and real-life data. About a third of the patients had ADRs, but discontinuation of the treatment because of ADRs was relatively uncommon.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- idiopathic pulmonary fibrosis
- pirfenidone
- forced vital capacity
- comorbidities
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas